Low-dose interleukin-2 effectively treats patients with psoriasis by regulating Th17/Treg imbalance and cytokine abnormality in peripheral blood
10.3760/cma.j.cn141217-20240703-00206
- VernacularTitle:低剂量IL-2治疗银屑病的临床疗效及其逆转外周血Th17/Treg失衡细胞因子紊乱的作用研究
- Author:
Wenpeng ZHAO
1
;
Yan LIU
;
Zusha QIAO
Author Information
1. 山西医科大学第二医院风湿免疫科，太原 030001
- Publication Type:Journal Article
- Keywords:
Psoriasis;
Interleukin-2;
Regulatory T cell;
T helper cell 17;
Immunotherapy
- From:
Chinese Journal of Rheumatology
2025;29(9):741-749
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the therapeutic effect of low-dose interleukin-2 (LdIL-2) on psoriasis and the regulatory role of peripheral blood Th17/Treg imbalance and cytokine disorder.Methods:45 psoriasis patients and 40 healthy individuals were collected from January 2021 to December 2022 in the Second Hospital of Shanxi Medical University. All patients were given with MTX (7.5 mg/week) for 12 weeks, followed by LdIL-2 (50×10 5 U/d×2 weeks×3 courses) until the 24 th week. PASI and ACR20 were collected at the 0, 12th and 24th weeks. Th17, Treg cell, IL-17 and IL-10 were detected. Statistical analysis included t-test, generalized estimating equations, Wilcoxon analysis, Chi-Square Test, Pearson linear correlation analysis, Spearman rank correlation analysis, etc. Results:①The number of patients who reached PASI50/75 in the 24 th week(31,10) was significantly higher than in the 12th week (14, 1), and the differences were statistically significant ( χ2=15.059, P<0.001; χ2=7.111, P=0.004). ②Compared the 0 week with the 24th week, Th17 cell was decreased [1.520%(0.985%, 2.005%) vs. 0.830%(0.675%, 1.125%), H=25.493, P<0.001], Treg cell was increased [3.010%(2.255%, 3.615%) vs.5.190%(4.605%, 6.030%), H=152.106, P<0.001], Th17/Treg ratio also was decreased [0.547(0.348, 0.712) vs. 0.170(0.105, 0.225), H=47.025, P<0.001], and the differences were statistically significant. ③Compared the 0 week with the 24th week, IL-17 was decreased [(19.7±8.7)pg/ml vs. (14.20±6.0)pg/ml, F=21.814, P<0.001], IL-10 was increased [(2.01±0.97)pg/ml vs. (2.62±0.92)pg/ml, F=11.230, P=0.004], IL-17/IL-10 ratio also was decreased [10.644(5.925, 14.705) vs. 5.410(3.455, 7.180), H=16.647, P<0.001], and the differences were statistically significant. ④The correlation analysis showed that PASI were significantly positively correlated with Th17 cells( r=0.598, P<0.001), Th17/Treg( r=0.772, P<0.001), IL-17( r=0.500, P<0.001) and IL-17/IL-10( r=0.776, P<0.001), and significantly negatively correlated with Treg cells( r=-0.822, P<0.001) and IL-10( r=-0.715, P<0.001). Conclusion:LdIL-2 can effectively reverse Th17/Treg imbalance and cytokine disorder in psoriasis patients, significantly alleviate the condition, and has good safety.
